FSHB c.-211G>T

FSHB c.-211G>T — The Promoter Variant That Quietly Lowers FSH Throughout Life

Every egg maturation cycle and every sperm development program depends on a precise
dose of follicle-stimulating hormone (FSH). FSH is a two-subunit hormone: the alpha
subunit is shared with LH, TSH, and hCG, but the beta subunit (FSHB) | The beta
subunit determines FSH's receptor-binding specificity — it is the component that
targets FSH exclusively to ovarian granulosa cells and testicular Sertoli cells
is unique to FSH and sets its production rate. The c.-211G>T variant sits in the
FSHB promoter, 211 base pairs upstream of the transcription start site, and quietly
reduces how much of this hormone the pituitary can make — with consequences that play
out across a person's entire reproductive life.

The Mechanism

The G-to-T substitution at position -211 falls within a conserved binding site for
LHX3 | LIM homeobox transcription factor 3, expressed in pituitary gonadotroph cells;
essential for FSH but not LH production,
a homeodomain protein that drives basal FSHB expression in pituitary gonadotroph cells.
Functional studies show that LHX3 binds with measurably lower affinity to the T-allele
promoter, and when the T allele is tested in luciferase reporter assays, the promoter
produces only 46–58% of the transcriptional output of the G allele | Measured in
LβT2 gonadotroph cells using matched promoter constructs; reproduced independently
by two research groups.

This reduced promoter activity translates directly into lower circulating FSH. The
effect is additive: heterozygotes (GT) have roughly 13–16% less FSH than GG individuals,
and TT homozygotes have approximately 40–50% less FSH | Both figures replicated in
independent Baltic, Estonian, and German cohorts; the Estonian study used n=554 healthy
men. Because FSH drives Sertoli cell
proliferation during fetal and neonatal development — a window that determines permanent
testicular size and spermatogenic capacity — the effect on males extends well beyond
adult hormone levels.

The Evidence

In males, the consequences of lifelong reduced FSH are measurable at the organ level.
A large Baltic cohort study | Grigorova et al., Genetically Determined Dosage of
Follicle-Stimulating Hormone Affects Male Reproductive Parameters. JCEM, 2011
of 1,054 men showed that TT homozygotes had ~20% smaller testicular volume (38 mL vs
47 mL), 21% lower inhibin-B (a direct Sertoli cell product), and lower testosterone
compared to GG carriers. FSH reduction per T allele was 0.51 IU/L in combined
meta-analysis. The T allele was enriched among infertile men in multiple cohorts:
one study of 1,029 infertile men and 554 fertile controls | Tüttelmann et al., JCEM, 2012
found TT genotype in 2.4% of infertile vs 1.1% of fertile men. In non-obstructive
azoospermia patients undergoing TESE (testicular sperm extraction) | Busch
et al., JCEM, 2019, the T allele
significantly predicted failed sperm retrieval, an association that held even after
adjusting for FSH levels — suggesting a direct effect on spermatogenesis beyond
the hormonal signal alone.

In females, a large genetic association study using UK Biobank data (up to 63,350 women)
| Ruth et al., Human Reproduction, 2016
demonstrated that each T allele lengthens the menstrual cycle by approximately 1 day
(0.16 SD; P=6×10⁻¹⁶) and delays menopause by 0.13 years, consistent with lower FSH
slowing ovarian follicle recruitment and depletion. The same T allele was
protective against endometriosis | OR 0.79, 95% CI 0.69–0.90; P=4.1×10⁻⁴; consistent
with FSH's role in promoting estrogen production from developing follicles
but increased the probability of nulliparity (OR 1.06), suggesting reduced conception
efficiency. For women undergoing IVF, a Brazilian study (n=140) | Trevisan et al.,
Genetic Testing and Molecular Biomarkers, 2019
found that GT carriers had significantly fewer antral follicles (8.0 vs 10.0; P=0.03),
fewer oocytes retrieved (3.0 vs 5.0; P=0.03), and nearly double the rate of poor
response to controlled ovarian stimulation (47.4% vs 26.5%; P=0.010).

Practical Implications

The T allele does not prevent fertility; it reduces FSH-driven amplification of the
reproductive signal. For carriers planning assisted reproduction, this has direct
protocol implications: lower baseline FSH may indicate a need for adjusted gonadotropin
dosing. For male T-allele carriers, the implications are most acute in azoospermia
evaluation — when TESE is being considered, the genotype may help predict sperm
retrieval probability. The variant is also relevant in interpreting unexpectedly normal
or low FSH in the context of reproductive difficulty: a "normal" FSH reading in a TT
carrier may represent relative FSH insufficiency for that individual's gonadal needs.

Interactions

rs11031006 (FSHB distal enhancer): This batch includes both the proximal promoter
variant (c.-211G>T, this SNP) and the distal enhancer SNP rs11031006, located ~26 kb
upstream of the FSHB transcription start site. The two SNPs are in moderate linkage
disequilibrium (r2 ~0.2–0.3 in Europeans) but have independent functional mechanisms:
c.-211G>T impairs LHX3 binding at the proximal promoter, while rs11031006 affects SF1
binding at the distal enhancer. Both reduce FSH transcription via different regulatory
inputs, and individuals carrying T alleles at both positions may experience a compounded
reduction in FSH output that is not captured by either SNP alone. Direct compound
analysis across both variants has not been published, but the additive pathway biology
is well-established.

FSHR rs6166 (N680S) + FSHB rs10835638: When FSH production is already reduced
(FSHB T allele) and the FSH receptor also operates at lower efficiency (FSHR rs6166
GG/Ser680Ser), the combined effect represents a dual impairment of the FSH axis —
reduced signal and reduced receptor sensitivity. A published compound analysis of
FSHB c.-211G>T and FSHR 2039A>G (rs6166) in 3,017 men confirmed that the FSHR
variant significantly modulated the already-dominant FSHB T-allele effect on FSH and
testicular volume. For IVF protocols, this dual-impairment signature may predict a
lower-than-expected response to standard FSH stimulation doses and would warrant
earlier dose escalation review. Proposed compound action: rs10835638 (GT or TT) +
rs6166 (GG) — "Dual FSH Axis Impairment: Low Production and Reduced Receptor
Sensitivity." Action type: monitoring + lifestyle (IVF protocol disclosure).
Evidence level: moderate.

IRF1/RAD50 rs13164856 + FSHB rs10835638: rs13164856 is a PCOS-susceptibility
tag SNP at 5q31 specifically associated with testosterone levels. Women carrying
the rs13164856 T allele (androgen-excess) alongside the FSHB T allele (low FSH)
may face compound reproductive challenges: elevated androgens combined with reduced
FSH-driven follicle development. This represents two distinct PCOS pathways converging
— androgen excess and gonadotropin insufficiency.